EN DE
Watch Compugen for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Compugen (CGEN) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Compugen stock $5.63, price $1.96, upside +187.2%, quality 81 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Israel · ISIN IL0010852080

C Compugen logo Some data Nov 8, 2026

Compugen

CGEN · US
Meets all rules

The stock costs 65% less than our calculation considers fair.

Fair value $5.63 · Strongly undervalued
Quality 81/100
Highly profitable · 47.6% net margin (TTM)
Generates free cash flow
Ranks above peers (11/12)
Revenue last quarter +107% vs. a year ago.
Mixed Growth (revenue 5y +105.2 %/yr in USD)
Wide moat 90/100 · thin data
Insiders sold $4,688 (6M)
Some data
Downbeat coverage
Watch Compugen for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$7.16 $0.5300 Fair Value $5.63 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range $0.5300 – $7.16 · fair‑value band $3.92 – $7.61 · the $1.96 price screens below the $5.63 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Compugen in your weekly email

Every Wednesday you see whether Compugen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.

Show moreShow less

The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.

Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors.

It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products.

The company was incorporated in 1993 and is headquartered in Holon, Israel.

Stock analysis

Compugen (CGEN) currently trades at $1.96, while our model-based Fair Value estimate is $5.63, implying the stock looks roughly 65% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $17.33 per share, and 23 of the 24 models we run sit above the $1.96 price.

Bear case: the Asset-Based group reads lowest at $0.9900, and 1 of the 24 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $3.92 (bear) to $7.61 (bull), the price of $1.96 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 81/100 (high quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Compugen reported revenue of $72.8M in FY2025 versus $6.0M in FY2021, a compound +86.6%/yr. Reported net income was $35.3M in FY2025.

Key figures

Market cap $185M Micro · P/E ratio 5.2 · P/S ratio 2.51 · EPS (TTM) $0.3800 · Net margin 47.6% · Return on equity 50.6% · Return on assets (EBIT) −13.6% (5-year average) · Operating margin −340%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 90 out of 100 (low confidence).

What moves the price

The share trades about 37% below its 52-week high and 33% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 187%, CGEN screens cheaper than that median.

Fair Value models

Bear $3.92 Fair Value $5.63 Bull $7.61
Price $1.96 · Upside +187.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.3259 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $4.11 $5.15 $8.10 76
Growth DCF $3.92 $5.36 $7.61 74
Owner Earnings $3.82 $6.17 $9.96 70
All 24 models by family
DCF Models
FCF DCF $4.11 $5.15 $8.10 76
Owner Earnings $3.82 $6.17 $9.96 70
5Y Revenue Exit $3.25 $4.48 $7.01 67
5Y EBITDA Exit $4.28 $6.55 $11.00 68
5Y P/E Exit $5.79 $11.76 $19.89 63
10Y Revenue Exit $3.55 $5.55 $6.54 63
10Y EBITDA Exit $4.16 $7.23 $12.34 61
10Y P/E Exit $5.00 $9.68 $17.32 57
Earnings-Based
Graham-Dodd $2.54 $17.69 $24.83 61
Lynch FV $9.14 $13.06 $16.98 59
PEG = 1.0 $9.14 $13.06 $16.98 55
EPV $2.74 $2.91 $3.05 70
Multiples
P/E Multiple $6.16 $8.21 $10.26 63
P/S Multiple $2.02 $2.69 $3.36 58
P/B Multiple $2.69 $3.59 $4.48 55
EV/EBIT $5.14 $6.55 $7.95 63
EV/EBITDA $4.45 $5.63 $6.80 64
EV/Revenue $2.54 $3.23 $3.92 52
Asset-Based
NCAV (Graham) $0.6500 $0.9900 $1.24 52
Growth DCF
Growth DCF $3.92 $5.36 $7.61 74
Rev-Margin DCF $3.46 $4.98 $8.19 66
Economic Profit
Residual Income $1.59 $2.34 $4.56 64
ROIC Compounder $2.83 $3.12 $3.40 68
Growth Earnings
Growth-Adj P/E $12.13 $17.33 $22.54 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 81/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 80
How much profit the company makes from its sales and capital
Quality Growth 100
Are margins and returns getting better?
Cashflow 82
Do the profits arrive as real cash?
Financial strength 80
Debt, balance sheet and risk of trouble
Investment 53
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 31
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 43
Distance to the 52-week high, does not count
New shares 64
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $4,688 and none bought.

  • SaleZurit LevineSVP, Business Development7× since Mar 26, 2026: 32,250 shares, avg. $2.34$75,370Jul 9, 202610b5-1 plan
  • SaleEran OphirPresident and CEO, Director3× since Apr 1, 2026: 15,625 shares, avg. $2.75$42,931Apr 24, 202610b5-1 plan

Plus 10 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 91/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+161.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+113.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+105.2%
Start year 2020 (pandemic). Over 10 years: +22.9% a year
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,574.8% (2020) → 43.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−38.0%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −39.4% a year for the price.

Watch CGEN, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (95 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Very negative
Recent news coverage is unusually downbeat.
Note from the team Nov 3, 2026
AI conclusion: The business draws strength from partnerships that deliver non-dilutive capital and a cash runway into 2029, yet its main weakness is the limited evidence of a durable moat amid typical biotech clinical risks.
Main risk: Any delay or inconclusive outcome for the COM701 ovarian program would stall pipeline progress and reduce the value created through existing partnerships.
Compugen's AI-driven Unigen platform continues to expand into new tumor targets while partnerships with AstraZeneca and Gilead provide non-dilutive capital. With a cash runway extending into 2029, the company can advance its COM701 ovarian program without immediate financing pressure, yet the key interim progression-free survival readout remains months away in early 2027. Will the extended runway translate into meaningful pipeline progress or simply prolong the wait for clinical validation?
Join the discussion →

Compare Compugen with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 11/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 81 · Top 25%
Fair Value upside +187.2% · Top 25%
Profitability
Return on equity (12 months) 50.6% · Top 25%
Return on assets 22.5% · Top 25%
Net margin (12 months) 47.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 107.0% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 5.2× · Cheapest 25%
P/B 1.81× · Cheaper than median
P/S (12 months) 2.51× · Cheapest 25%
Price / free cash flow (fiscal year) 5.9× · Cheapest 25%
EV/EBITDA 3.1× · Cheapest 25%
PEG 1.29× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)100 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs CGEN
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs CGEN
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs CGEN
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs CGEN
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs CGEN
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs CGEN
argenx SE ARGX $927.21 $908.40 −2% vs CGEN
CSL Limited CSL A$200.77 A$183.04 −9% vs CGEN
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs CGEN
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs CGEN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Compugen: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Compugen Fair Value". https://www.fairvalue-calculator.com/stock/CGEN

Frequently asked questions

Is Compugen (CGEN) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $5.63 versus a price of $1.96, about +187% upside (undervalued).
What is the fair value of CGEN?
Our model-based fair value for Compugen is $5.63 (as of Nov 8, 2026), built from audited fundamentals. The current price: $1.96.
What is the quality score of CGEN?
Compugen has a Quality Score of 81/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Compugen (CGEN)?
Our model-based price target is the fair value of $5.63 (as of Nov 8, 2026) from 24 valuation models. Cautious scenario $3.92, optimistic scenario $7.61. It is a calculation from audited fundamentals, not an analyst target.
What is the Compugen stock forecast for 2026?
Our models put fair value at $5.63, about +187% upside versus a price of $1.96 (undervalued). Cautious scenario $3.92, optimistic scenario $7.61. The calculation is refreshed regularly with new filings.
What is the revenue of Compugen (CGEN)?
Compugen reported trailing-twelve-month revenue of about $74.0M (latest available figure, as of Nov 8, 2026).
What growth is priced into Compugen (CGEN)?
For today's price to be fair in a discounted-cash-flow model, Compugen would have to grow free cash flow by -38.0 % per year for five years (discount rate 15.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +105.2 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of CGEN use?
Our models discount Compugen at 15.2 %: a base by market capitalisation (micro), damped by beta 2.82, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Compugen that is -38.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (15.2 %) and the same formula as our fair value.
How much growth has Compugen (CGEN) delivered so far?
Over the past 5 years revenue at Compugen grew +105.2 % a year. The price currently implies free-cash-flow growth of -38.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Compugen (CGEN) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Compugen (-38.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Compugen (CGEN)?
The free-cash-flow yield on the price is 16.89 %: that much free cash flow Compugen produces per unit of market value. When it exceeds the discount rate of our models (15.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Compugen (CGEN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Compugen it is $5.63 per share (as of Nov 8, 2026), against a price of $1.96. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Compugen stock overvalued or undervalued in 2026?
As of Nov 8, 2026, CGEN trades below its calculated fair value: price $1.96, fair value $5.63, a gap of about +187% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CGEN?
No. The price is what the market pays today ($1.96); the fair value is what the company's own numbers justify ($5.63). For Compugen the two are $3.67 per share apart. That gap is exactly why we show both numbers side by side.
How much is Compugen worth?
The market values Compugen at about $185M (market capitalisation, as of Nov 8, 2026). Per share that is $1.96; our models calculate a fair value of $5.63 per share.
What do the bullish and bearish scenarios say about CGEN?
Our models span a range for Compugen: cautious scenario $3.92, base $5.63, optimistic $7.61 per share (as of Nov 8, 2026, price $1.96). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CGEN?
Compugen trades at a price-to-earnings ratio of 5.2 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $5.63 is built from several models across several years. Other multiples: PEG 1.3, P/B 1.8, P/S 2.5, EV/EBITDA 3.1.
What is the PEG ratio of CGEN?
The PEG ratio of Compugen is 1.29 (P/E divided by earnings growth, as of Nov 8, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Compugen (CGEN)?
Balance-sheet figures for Compugen (as of Nov 8, 2026): return on equity 50.6%. They feed the Quality Score of 81/100, which measures business quality independently of the share price.
How far is CGEN from its 52-week high?
Compugen trades at $1.96, about 37% below its 52-week high of $3.10 and 33% above the low of $1.47 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $5.63 is for.
Which stocks are comparable to Compugen?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Compugen stock attractive at the current price?
The data as of Nov 8, 2026: price $1.96, calculated fair value $5.63 (+187%), Quality Score 81/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CGEN calculated?
We run Compugen through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $5.63 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Compugen currently trades 65% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Compugen (CGEN)?
The closing price on Nov 6, 2026 was $1.96. Our model-based fair value is $5.63, about +187% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Compugen right now?
The rarer combination: high quality (81/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case ($3.92). The market is more pessimistic than our downside scenario. A fairly wide model range ($3.92 to $7.61) leaves room in how you read the outcome.

Key figures of Compugen

How large is the market capitalisation of Compugen (CGEN)?
The market capitalisation of Compugen is $185M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Compugen (CGEN)?
The price-to-sales ratio of Compugen is 2.51 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Compugen (CGEN)?
Earnings per share at Compugen are $0.3800 (price ÷ EPS = P/E 5.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Compugen (CGEN)?
The net margin of Compugen is 47.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Compugen (CGEN)?
The return on equity (ROE) of Compugen is 50.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Compugen (CGEN)?
On an EBIT basis the return on assets of Compugen is −13.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Compugen (CGEN)?
The operating margin of Compugen is −340% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Compugen (CGEN)?
Revenue at Compugen is growing +107% versus a year earlier (3y avg +113%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does Compugen (CGEN) hold?
Compugen holds more cash than debt, $87.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Compugen in the live analysis

One click puts Compugen on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.